A Phase 2b, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects With Unresectable Pleural or Peritoneal Malignant Mesothelioma

Trial Profile

A Phase 2b, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects With Unresectable Pleural or Peritoneal Malignant Mesothelioma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Jul 2017

At a glance

  • Drugs Tremelimumab (Primary)
  • Indications Mesothelioma
  • Focus Therapeutic Use
  • Acronyms DETERMINE
  • Sponsors MedImmune
  • Most Recent Events

    • 17 Jul 2017 Results published in the Lancet Oncology
    • 05 Apr 2017 Results (n=376) assessing relationship of exposure with OS, and the impact of potential confounders, presented at the 108th Annual Meeting of the American Association for Cancer Research
    • 10 Aug 2016 This trial was completed in Belgium (end date: 18 Apr 2016) according to European Clinical Trials Database record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top